Leading medical device manufacturer Medtronic will report Q3 fiscal 2016 earnings on March 1st. (Fiscal years end with April.) We expect the company to see growth coming in from the market expansion due to new product launches and the synergies associated with the Covidien acquisition. Moreover, strong adoption of the company’s wireless pacemaker, the Micra TPS (Transcatheter Pacing System), might have provided incremental revenues in Q3. However, macro and foreign currency headwinds continue to offset Medtronic’s growth across its businesses. Foreign currency headwinds alone likely affected the company’s revenues to by a significant degree in Q3. Nevertheless, Medtronic’s successful three prong growth strategy, which revolves around therapy innovation, globalization and economic value, will continue to drive future growth.

from Forbes – Tech http://ift.tt/21wPna8
via IFTTT